Current Report Filing (8-k)
July 19 2021 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): July 19, 2021
AIKIDO PHARMA INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
000-05576
|
|
52-0849320
|
(State or other jurisdiction
of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification
No.)
|
One Rockefeller Plaza, 11th Floor, New York, NY
|
|
10020
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (212) 745-1374
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13a-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common stock, par value $0.0001 per share
|
|
AIKI
|
|
The NASDAQ Capital Market
|
On July 19, 2021, the Board of Directors
of AIkido Pharma Inc., (“the Company”) confirmed its intention to hold the Company's 2021 Annual Meeting of Shareholders (the
“2021 Annual Meeting”) on Tuesday, October 5, 2021. The time and location of the 2021 Annual Meeting, and the matters to be
considered, will be as set forth in the Company's definitive proxy statement for the 2021 Annual Meeting to be filed in due
course with the Securities and Exchange Commission (“SEC”).
Since the date of the 2021 Annual Meeting
has been changed by more than 30 days from the anniversary date of the Company’s last annual meeting of shareholders, the Company
is informing shareholders of this change and the updated deadline for shareholders to submit nominations for director or proposals for
consideration at the 2021 Annual Meeting in accordance with the rules and regulations of the SEC and the Company’s By-laws (the
“Bylaws”). Accordingly, shareholders wishing to nominate a candidate for director or to propose other business at the
2021 Annual Meeting must ensure proper notice is received by the Company at its offices no later than August 2, 2021. The notice must
include all of the information required by the Company’s By-laws.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
AIKIDO PHARMA, INC.
|
|
|
|
Date: July 19, 2021
|
By:
|
/s/ Anthony Hayes
|
|
Name:
|
Anthony Hayes
|
|
|
Chief Executive Officer
|
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Sep 2023 to Sep 2024